



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. E116351673675 US with sufficient postage on the date indicated below and in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If checked, two copies of this correspondence are enclosed.

Dawn M. Janelle

Signature

Date of Deposit: NOV. 18, 2005

Dawn M. Janelle

Printed name of person mailing correspondence

| | | | |
|-------------|----------------------|-----------|---------|
| Applicant: | DONG, Zheng Xin | Art Unit: | Unknown |
| Serial No.: | 10/554,240 | Examiner: | Unknown |
| Filed: | Oct. 21, 2005 | | |
| Title: | SOMATOSTATIN VECTORS | | |

**INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO
CHARGE DEPOSIT ACCOUNT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination)

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a Petition under 37 CFR 1.97(d)(2), and

a \$130.00 petition fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.

(Filed after payment of issue fee)

Some of the listed references were cited in a European Search Report in a counterpart European application or cited in a communication from a foreign patent office in a counterpart foreign application.

- Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of each reference noted thereon.
- Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of selected references noted thereon. As per the change to 37 CFR 1.98(a)(2) published in the September 21, 2004 Federal Register and effective as of October 21, 2004, in which the requirement for a copy of each U.S. Patent or U.S. Patent application publication listed in an IDS has been eliminated regardless of the filing date of the application (unless required by the Office), copies of any United States Patent or Patent Publications are not enclosed.
- Copies of the reference(s) noted on the enclosed form PTO/1449 (N pages, reproduced form) were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)). Applicants request that copies of art in U.S. Application Serial No. [] cited on the enclosed PTO/1449 form be transferred to the present U.S. Application Serial No. [].

Concise Explanation Requirement (non-English references):

- The "concise explanation" requirement for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - the explanation provided on the attached sheet.
 - the explanation provided in the Specification.
 - submission of the enclosed International Search Report.
 - the enclosed English language abstracts.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Statement Under 37 CFR 1.97(e):

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Method of payment:

- A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.


Respectfully submitted,

BIOMEASURE, INCORPORATED

By Pamela C. Ball

Pamela C. Ball, Agent for Applicant(s)
Registration No.: 53,963

Dated: Nov 18 2005
27 Maple Street
Milford, Massachusetts 01757
Phone: (508)478-0144
Facsimile: (508) 473-3531



| | | | |
|-------------------------------------------------------------------------------------------|--|-------------------------------------|-----------------------------------|
| PTO-1449 REPRODUCED | | ATTORNEY DOCKET NO. 119P/PCT2/US | APPLICATION NO. 10/554,240 |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) | | APPLICANT DONG, Zheng Xin | |
| | | FILING DATE Oct. 21, 2005 | GROUP/EXAMINER Unknown/Unknown |

U.S. PATENT DOCUMENTS

| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|-------------------------------|---|-----------------|---------------|------------------|-------|---------------|----------------------------------|
| | A | 5,482,698 | Jan. 9, 1996 | Griffiths | | | |
| | B | 5,525,338 | Jun. 11, 199 | Goldenberg | | | |
| | C | 5,795,909 | Aug. 18, 1998 | Shashoua et al. | | | |
| | D | 5,843,903 | Dec. 1, 1998 | Schally et al. | | | |
| | E | 5,948,750 | Sep. 7, 1999 | Garsky et al. | | | |
| | F | 6,077,499 | Jun. 20, 2000 | Griffiths et al. | | | |
| | G | 6,191,290 | Feb. 20, 2001 | Safavy | | | |
| | H | 6,207,660 | Mar. 27, 2001 | Sessler et al. | | | |
| | I | 2002 0094964 | Jul. 18, 2002 | Chen et al. | | | |
| | J | 2002 0115596 | Aug. 22, 2002 | Garsky et al. | | | |
| | K | 2003 0064053 | Apr. 3, 2003 | Liu et al. | | | |
| | L | 2003 0064984 | Apr. 3, 2003 | Ng et al. | | | |
| | M | 2005 0070470 | Mar. 31, 2005 | Coy et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|--|---|------------------------|---------------|----------|-------|---------------|-----------------------|
| | N | 96/40210 | Dec. 19, 1996 | WIPO PCT | | | |
| | O | 97/19954 | Jun. 5, 1997 | WIPO PCT | | | |
| | P | 02/34237 | May 2, 2002 | WIPO PCT | | | |
| | Q | 02/87497 | Nov. 7, 2002 | WIPO PCT | | | |
| | R | 0 450 461 (A2, A3, B1) | Oct. 9, 1991 | EP | | | |
| | S | 0 450 480 (A2, A3, B1) | Oct. 9, 1991 | EP | | | |
| | T | 1 118 336 | Jul. 25, 2001 | EP | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U | FUSELIER, et al., "An adjustable release rate linking strategy for cytotoxin-peptide conjugates," <i>Bioor. Med. Chem. Lett.</i> , 2003, 10:799-803. |
| V | HUANG, et al., "Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis," <i>Chem. Biol.</i> , 2000, 7:453-461. |
| W | KOVACS, et al., "Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone," <i>PNAS</i> , 1997, 94:1420-1425. |
| X | NAGY, et al., "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin," <i>PNAS</i> , 95:1794-1799. |
| Y | SAFAVY, et al., "Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery," <i>Bioconjug. Chem.</i> , 2003, 14:302-310 |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|